News
ESMO Recommendations for the Treatment of Low-Risk Myelodysplastic Syndrome
The priority in the treatment of low-risk myelodysplastic syndrome (MDS) is managing cytopenia, primarily anemia, as well as neutropenia and thrombocytopenia. The following summary of recommendations sets the criteria for response to treatment and lists current therapeutic options for the 1st and 2nd lines.
Effect of Luspatercept Treatment in Patients with MDS/MPN-RS-T
The presented post hoc analysis of the MEDALIST study demonstrates the effect and good tolerance of…
Association between Hypothyroidism, Depression, and Anxiety Disorder – Results of Meta-Analyses
The prevalence of autoimmune thyroiditis in the USA ranges between 4 and 13%. Subclinical…
A Look at Tongue and Its Care from the Perspective of Western and Traditional Chinese Medicine
The tongue is a valuable diagnostic tool used in both Traditional Chinese Medicine (TCM) and…
Management of Adverse Effects During Maintenance Treatment of AML Patients
The randomized phase III study QUAZAR AML-001 evaluated the maintenance treatment of acute myeloid…
SCOPE 2021 – State of Osteoporosis and Its Treatment in European Countries
The SCOPE 2021 project (The Scorecard for Osteoporosis in Europe) by the International Osteoporosis…
Risk of Subsequent Fractures in Postmenopausal Women After Initial Fracture
Osteoporosis is associated with an increased risk of fractures. The prospective analysis presented…
Laboratory Safety of Dupilumab Treatment in Children with Atopic Dermatitis Aged 6 Months to 6 Years
Previous clinical studies in children aged 6–12 years with moderate-to-severe atopic dermatitis…
Long-term Safety and Efficacy of Ozanimod in the Treatment of Relapsing Forms of MS
Ozanimod is classified as a modulator of sphingosine-1-phosphate (S1P) receptors types 1 and 5. It…
How does empagliflozin perform in older type 2 diabetics compared to liraglutide and sitagliptin in terms of HHF and MACE risks?
Last fall, a study was published in JAMA Network Open, focusing on older patients with type 2…